Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Arcturus Therapeutics Holdings Inc is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 118 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$29.22|
|52-week range||$24.87 - $129.71|
|50-day moving average||$32.71|
|200-day moving average||$44.17|
|Wall St. target price||$80.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-15.87%|
|3 months (2021-05-03)||-18.79%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
|Revenue TTM||$9 million|
|Gross profit TTM||$-48,307,000|
|Return on assets TTM||-27.04%|
|Return on equity TTM||-64.24%|
|Market capitalisation||$870.1 million|
TTM: trailing 12 months
There are currently 3.7 million Arcturus Therapeutics shares held short by investors – that's known as Arcturus Therapeutics's "short interest". This figure is 6.6% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting Arcturus Therapeutics shares can be evaluated.
Arcturus Therapeutics's "short interest ratio" (SIR) is the quantity of Arcturus Therapeutics shares currently shorted divided by the average quantity of Arcturus Therapeutics shares traded daily (recently around 544415.86608443). Arcturus Therapeutics's SIR currently stands at 6.87. In other words for every 100,000 Arcturus Therapeutics shares traded daily on the market, roughly 6870 shares are currently held short.
However Arcturus Therapeutics's short interest can also be evaluated against the total number of Arcturus Therapeutics shares, or, against the total number of tradable Arcturus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcturus Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Arcturus Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1732% of the tradable shares (for every 100,000 tradable Arcturus Therapeutics shares, roughly 173 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arcturus Therapeutics.
Find out more about how you can short Arcturus Therapeutics stock.
We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.
Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.
Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $24.87 up to $129.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.7124. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.